wck 2349
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01875939)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DNA topoisomerase IIIINHIBITOR
topB inhibitor
- DNA gyraseINHIBITOR
DNA gyrase inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- wck 2349
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02244827 | Phase 1 | Sep 1, 2014 | University of Miami, Wockhardt |
| NCT02253342 | Phase 1 | Sep 1, 2014 | Clinartis, Wockhardt |
| NCT02217930 | Phase 1 | Aug 1, 2014 | Spaulding Clinical Research Inc., Wockhardt |
| NCT01875939 | Phase 1 | Jun 1, 2013 | PPD, Wockhardt |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Wockhardt | For profit | 4 | 4 | 1 | 2013 |
| Clinartis | For profit | 1 | 0 | 1 | 2014 |
| PPD | For profit | 1 | 0 | 1 | 2013 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2014 |
| University of Miami | Academic/Hospital | 1 | 0 | 1 | 2014 |
5 organizations
Page 1 / 1